Vi-DT 伤寒结合疫苗在健康菲律宾婴幼儿中二期试验的免疫原性、安全性与反应原性:初步报告
在菲律宾蒙廷卢帕市开展的随机、观察者盲法二期研究,纳入285名6–23月龄婴幼儿,按年龄分层后每层76名接种Vi-DT(25 µg)、19名接种安慰剂。单剂Vi-DT后全部受试者血清阳转,安慰剂组为7%;抗Vi IgG几何平均滴度(GMT)Vi-DT组为444.38,安慰剂组为0.41,p<0.0001。疫苗安全且耐受良好。
要点
- 单剂Vi-DT(25 µg)在6–23月龄婴幼儿中全部血清阳转,安慰剂组仅7%。
- 抗Vi IgG GMT Vi-DT组为444.38,安慰剂组为0.41(p<0.0001),各年龄层模式相似。
- Vi-DT疫苗报告安全且耐受良好。
核心结论
- Vi-DT疫苗在6–23月龄儿童中具有免疫原性、安全且耐受良好。
研究设计与样本
- 随机、观察者盲法二期研究,在菲律宾蒙廷卢帕市开展,纳入285名6–23月龄参与者并按年龄分层。
主要发现
- 每个年龄层76名参与者接种Vi-DT、19名接种安慰剂。
- 单剂Vi-DT后全部参与者血清阳转,安慰剂组为7%。
- 抗Vi IgG GMT Vi-DT组为444.38[95% CI(400.28;493.34)];安慰剂组给药后GMT无变化,为0.41[95% CI(0.33;0.51),p<0.0001]。
- 各年龄层报告相似的免疫原性模式,疫苗报告安全且耐受良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Typhoid fever remains an important public health problem in developing countries and is endemic in many parts of Asia and Africa where the incidence of disease typically peaks in school-aged children. Age restrictions and other limitations of existing oral live-attenuated typhoid and parenteral Vi polysaccharide vaccines have triggered the development of Vi conjugate vaccines with improved immunological properties, use in younger age range, and longer durability of protection. We present the safety, reactogenicity, and immunogenicity data from a Phase II study after a single dose of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) conducted in 6-23-month old Filipino children. METHODS: This is a randomized, observer-blinded Phase II study to assess the immunogenicity, safety and reactogenicity of Vi-DT compared to placebo, conducted in Muntinlupa City, The Philippines. Participants aged 6-23 months were enrolled and randomized to Vi-DT (25 µg) or placebo (0.9% sodium chloride) and evaluated for immunogenicity and overall safety 28 days post vaccination. RESULTS: A total of 285 participants were enrolled and age-stratified: 6 to < 9 months, 9-12 months, and 13-23 months. Seventy-six (76) participants received Vi-DT and 19 received placebo per each strata. All participants seroconverted after a single dose of Vi-DT versus 7% of placebo recipients. Anti-Vi IgG GMT was 444.38 [95% CI (400.28; 493.34)] after a single dose of Vi-DT; there was no change in GMT after placebo administration, 0.41 [95% CI (0.33; 0.51), p < 0.0001]. A similar pattern of immunogenicity was reported across all age strata. The vaccine reported to be safe and well tolerated. CONCLUSIONS: Vi-DT vaccine was immunogenic, safe, and well tolerated in children aged 6-23 months. ClinicalTrials.gov registration number: NCT03527355.
引用
- Capeding MR, Alberto E, Sil A, et al. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. Vaccine. 2019. PMID: 31585725. doi:10.1016/j.vaccine.2019.09.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。